LIGAND PHARMACEUTICALS INC (LGND) Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both targeting multiple myeloma, as well as Rylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in both adult and pediatric patients. In the realm of infectious diseases, Ligand offers Veklury for moderate to severe COVID-19, Vaxneuvance for preventing invasive Streptococcus pneumoniae disease, and Pneumosil, a pneumococcal conjugate vaccine designed to protect children from pneumonia. Bone health solutions comprise Teriparatide injection for osteoporosis and Duavee for postmenopausal osteoporosis. Other key offerings include Zulresso, a Captisol-enabled formulation of brexanolone for postpartum depression; Nexterone, a Captisol-enabled amiodarone; and Noxafil-IV, a Captisol-enabled posaconazole for intravenous administration. The company’s comprehensive product lineup further extends to the Aziyo portfolio, featuring pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune disorders; Vivitra for breast cancer; Bryxta and Zybev for a variety of indications; and Minnebro for managing hypertension. Beyond its own commercialized products, Ligand Pharmaceuticals collaborates with partners on numerous programs currently undergoing clinical development, targeting conditions such as cancer, seizure disorders, diabetes, cardiovascular ailments, muscle wasting, hepatic and renal diseases, and various other serious illnesses. The company also directly supplies Captisol materials, a proprietary technology frequently integrated into many of its drug formulations. Established in 1987, Ligand Pharmaceuticals is headquartered in Emeryville, California.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Ligand Pharmaceuticals Incorporated NASDAQ:LGND Healthcare · Biotechnology
Mkt Cap $6.46B
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release ● Major ⚠ 4
Ligand Reports Third Quarter 2026 Financial Results
Ligand reported Q3 2026 royalty revenue of $70.3 million, up 51% year-over-year, driven by the XOMA Royalty portfolio and momentum in Filspari and Ohtuvayre royalties.
The headline was mixed: total revenues and income fell 32% to $78.7 million only because the prior year included $53.1 million of Pelthos divestiture income (up 26% excluding it), while GAAP results swung to a net loss of $28.5 million and adjusted EPS declined 14% to $2.67 on XOMA integration costs and mark-to-market losses.
Management raised full-year 2026 adjusted diluted EPS guidance to $9.50-$9.75 from $9.00-$9.50 and reaffirmed total revenue guidance of $270-$310 million, with $750 million of deployable capital for further royalty deals.
Quarter highlights included the completed XOMA acquisition (portfolio now over 200 assets), a $23 million Ryjunea royalty purchase, and up to $47 million committed to AvenCell's CAR-T pipeline.
• 3d ago AI analysis › Press Release
Ligand to Participate in November Investor Conferences
Ligand Pharmaceuticals announced senior management will participate in three November investor conferences, including the UBS Global Healthcare Conference and Stifel 2026 Healthcare Conference.
Management will hold one-on-one investor meetings on November 9 and November 30 and join a Stifel fireside chat on November 10 at 10:40 a.m. ET.
The release contains no financial or operational updates and is routine investor-relations scheduling.
• 5d ago AI analysis › Press Release
Ligand to Host Investor Day on December 8, 2026
Ligand Pharmaceuticals will host its annual Investor Day on December 8, 2026, from 10:30 a.m. to 12:00 p.m. ET at the Harvard Club of New York City.
Presentations from CEO Todd Davis, CFO Tavo Espinoza and other senior management will cover strategy, investment activity, the royalty portfolio, and long-term financial outlook. Palvella Therapeutics CEO Wes Kaupinen will guest speak on QTORIN rapamycin, in development for multiple rare disease indications.
The event is a scheduling notice with no new financial results or guidance; a live webcast will be available via Ligand's investor relations page.
• 10d ago AI analysis › Press Release
Ligand to Report Third Quarter 2026 Financial Results on October 29, 2026
Ligand Pharmaceuticals announced it will report third quarter 2026 financial results on Thursday, October 29, 2026.
A conference call to discuss the results and provide a general business update begins at 8:30 a.m. Eastern time, with live and replay webcasts available on the company's investor relations site.
This is a scheduling notice only; no results or guidance were disclosed.
• 17d ago AI analysis › Press Release ⚠ 2
Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million
Ligand Pharmaceuticals entered a financing agreement with AvenCell Therapeutics worth up to $47 million to advance AvenCell's allogeneic CAR-T pipeline.
Ligand committed up to $41 million for a mid single-digit to low double-digit royalty on worldwide net sales of AvenCell assets, funded in four tranches tied to clinical milestones, plus up to $6 million in a Series C round.
The deal adds exposure to AvenCell's lead programs AVC-201 (relapsed/refractory AML, Phase 1b expansion) and AVC-203 (B-cell malignancies, Phase 1a), expanding Ligand's royalty portfolio of more than 200 assets.
• 1mo ago AI analysis › Press Release
Sydnexis Announces Royalty Agreement with Ligand for Ryjunea®
Ligand Pharmaceuticals (LGND) agreed to pay $23 million upfront to Sydnexis for a 100% interest in EMEA royalty rights tied to net sales of Ryjunea (SYD-101), which is licensed to Santen and already approved in the EU and UK.
Sydnexis retains all U.S. and non-Santen-territory rights and plans potential U.S. commercialization in 2027 pending FDA review; Ligand's royalty stream depends on Santen's ex-U.S. sales.
For LGND, the deal is a characteristic royalty-aggregation acquisition on an already-approved product, adding a modest new income stream for $23M.
• 1mo ago AI analysis › Press Release ⚠ 1
Primrose Bio® Raises Significant Growth Capital Investment Led by Signet Healthcare Partners
Primrose Bio closed a growth capital round led by new investor Signet Healthcare Partners, with participation from existing investors including Ligand Pharmaceuticals (LGND).
In conjunction with the financing, Signet's James Gale joined Primrose's board; proceeds will expand Pfenex, Prima RNApols, and PeliCRM197 production technologies.
For LGND this is modest positive validation of its portfolio company, but the round size and Ligand's stake economics were not disclosed, so direct financial impact is limited.
• 1mo ago AI analysis › Press Release ⚠ 3
Ligand Acquires Royalty and Milestone Interest in Santen’s Ryjunea® from Sydnexis for $23 Million
Ligand Pharmaceuticals acquired a royalty and milestone interest in Santen's Ryjunea, the first and only approved pharmacologic treatment to slow pediatric myopia in the EU and UK, from Sydnexis for a $23 million upfront payment.
The acquired rights include a tiered low-double-digit to high-teens royalty on Ryjunea net sales in Europe, the Middle East, and Africa, plus certain milestones. Santen licensed EMEA rights from Sydnexis in 2021, with approvals from the European Commission in June 2025 and the UK MHRA in October 2025.
Ryjunea is a once-nightly 0.01% atropine eye drop for children aged 3-14; Santen estimates 14 million patients in Europe were affected by myopia in 2025, with roughly 1 in 3 children and adolescents projected to be affected by 2050.
The bolt-on fits Ligand's royalty-aggregation model of more than 200 assets, but the payoff depends entirely on Santen's EMEA commercial execution and no sales or royalty guidance was provided.
• 1mo ago AI analysis › Press Release
Ligand to Participate in September Investor Conferences
Ligand Pharmaceuticals announced that senior management will participate in three upcoming investor conferences during September.
The scheduled events include the Wells Fargo Healthcare Conference in Boston on Sept. 8, the Citi 2026 Biopharma Back to School Conference in New York on Sept. 10, and the H.C. Wainwright 28th Annual Global Investment Conference in New York on Sept. 14.
Management will also host one-on-one meetings with investors attending these conferences.
• 2mo ago AI analysis › Press Release ● Major
Ligand Reports Second Quarter 2026 Financial Results
Ligand reported Q2 revenue of $63.7 million, up 34% year-over-year, driven by a 32% increase in royalty revenue to $48.0 million. Adjusted EPS reached $2.37, reflecting strong year-over-year growth supported by gains from its royalty portfolio and strategic investments.
The company closed the XOMA Royalty acquisition, adding over 120 assets, and completed a $700 million 0% convertible debt financing. These moves significantly expand Ligand's portfolio and strengthen its capital position with $1.36 billion in cash and equivalents.
Management reaffirmed full-year revenue guidance of $270 million to $310 million and raised the low end of its Adjusted EPS guidance range to $9.00 to $9.50. The increase is attributed to cost synergies from the XOMA deal and incremental interest income from the new notes.
• 2mo ago AI analysis › Press Release
Ligand to Report Second Quarter 2026 Financial Results on August 6, 2026
Ligand Pharmaceuticals announced that it will report its second quarter 2026 financial results on Thursday, August 6, 2026.
The company will hold a conference call at 8:30 a.m. Eastern time to discuss the results and provide a business update.
Access to the live and replay webcasts is available on Ligand's investor relations website.
• 3mo ago AI analysis › Press Release ● Major ⚠ 1
XOMA Royalty Announces Closing of Its Acquisition by Ligand
Ligand Pharmaceuticals has completed its acquisition of XOMA Royalty Corporation, paying $39.00 in cash per share for all outstanding shares.
XOMA stockholders also received a Contingent Value Right (CVR) representing 75% of net proceeds from certain pending litigation at XOMA.
As a result of the transaction closing, XOMA Royalty's common stock has ceased trading on the Nasdaq stock exchange.
• 3mo ago AI analysis › Press Release ● Major ⚠ 2
Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets
Ligand Pharmaceuticals completed its acquisition of XOMA Royalty for $39.00 per share in cash, representing a total equity value of approximately $739 million. XOMA stockholders also received one non-transferable Contingent Value Right per share tied to pending litigation proceeds.
The transaction adds seven commercial products, including Roche's VABYSMO and Servier's OJEMDA, and 14 late-stage programs, more than doubling Ligand's portfolio to over 200 biopharmaceutical assets.
Management expects the deal to be immediately accretive, adding approximately $0.50 and $1.50 per share to adjusted earnings in 2026 and 2027, respectively. An updated five-year outlook will be provided at the Investor Day on December 8, 2026.
• 3mo ago AI analysis › Press Release ● Major
Ligand Announces Closing of Convertible Senior Notes Offering
Ligand Pharmaceuticals closed a $700 million offering of 0.00% convertible senior notes due 2031, generating net proceeds of approximately $678.2 million.
The company allocated about $72.9 million to hedge transactions and repurchased 228,859 shares of common stock for $60.0 million at a price of $262.17 per share to offset potential dilution upon conversion.
Remaining proceeds are earmarked for general corporate purposes and investments, including the previously announced acquisition of XOMA Royalty Corporation.
• 4mo ago AI analysis › Press Release ● Critical
Ligand Announces Pricing of Upsized $625 Million Convertible Senior Notes Offering
globenewswire.com • 4mo ago Press Release
Ligand Announces Proposed Offering of $550 Million of Convertible Senior Notes Due 2031
Ligand Pharmaceuticals announced its intention to offer $550 million aggregate principal amount of convertible senior notes due 2031 in a private placement, with initial purchasers receiving a 13-day option to buy an additional $82.5 million.
The company expects to use a portion of the net proceeds to enter into convertible note hedge and warrant transactions and to repurchase up to $75 million of its common stock to offset potential dilution upon conversion.
Remaining net proceeds will be allocated for general corporate purposes, including potential investments in complementary businesses and the previously announced acquisition of Xoma Royalty Corporation.
• 4mo ago AI analysis › Press Release
Ligand Announces 2026 Investor Day in New York City
Ligand Pharmaceuticals announced it will host an Investor Day in New York City on December 8, 2026.
The event will feature presentations from senior management covering the company’s strategy, recent investment activity, royalty portfolio, and long-term financial outlook.
A live webcast will be available via the company’s Investor Relations website, with detailed agenda and dial-in information to be provided closer to the date.
• 4mo ago AI analysis › Press Release
Ligand to Participate in June Investor Conferences
Ligand Pharmaceuticals announced its senior management team will participate in two upcoming investor conferences in June 2026.
The company will hold one-on-one meetings at the Stifel Boston Cross Sector Conference on June 3 and a fireside chat at the Goldman Sachs Global Healthcare Conference on June 10.
These are standard investor relations activities with no new business developments or financial disclosures.
• 5mo ago AI analysis › Press Release ● Major
Ligand Reports First Quarter 2026 Financial Results
globenewswire.com • 5mo ago Press Release
Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement
Ligand Pharmaceuticals completed a $15 million investment tranche in Orchestra BioMed, bringing total capital deployed under the royalty financing agreement to $40 million.
The funding is royalty-based and supports Orchestra BioMed's ongoing pivotal trials for AVIM Therapy and Virtue SAB.
Combined with a separate $20 million investment from Medtronic, Orchestra BioMed secured $35 million in total strategic capital on May 1, 2026.
• 5mo ago AI analysis › Press Release
Ligand to Participate in May Investor Conferences
Ligand Pharmaceuticals announced that its senior management team will participate in a series of investor conferences throughout May 2026.
Scheduled events include the H.C. Wainwright Royalty Company Conference, Bank of America Healthcare Conference, and RBC Capital Markets Global Healthcare Conference, featuring both fireside chats and one-on-one meetings.
CEO Todd Davis is set to speak at the H.C. Wainwright event on May 6 alongside Wes Kaupinen of portfolio company Palvella Therapeutics.
• 5mo ago AI analysis › Press Release ● Critical
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of XOMA Royalty Corporation
prnewswire.com • 6mo ago Press Release ● Critical
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator
Ligand Pharmaceuticals announced it will acquire XOMA Royalty for $39.00 per share in cash, representing a total equity value of approximately $739 million and a 14% premium to XOMA's 30-day volume weighted average price.
The transaction, expected to close in Q3 2026, is immediately accretive and prompted Ligand to raise its 2026 revenue guidance to $270 million to $310 million and adjusted EPS guidance to $8.50 to $9.50.
The acquisition adds over 120 assets including commercial products like Roche's VABYSMO and is expected to contribute $1.50 of accretion to adjusted EPS in 2027.
• 6mo ago AI analysis › Press Release ● Major
Ligand to Report First Quarter 2026 Financial Results on May 7, 2026
globenewswire.com • 6mo ago Press Release
Coave Therapeutics to present two posters at ARVO 2026, on first-in-class ligand-conjugated suprachoroidal vector and lead gene therapy program
globenewswire.com • 6mo ago Press Release ● Major
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS
globenewswire.com • 6mo ago 
